Patil Ajay, Sherbet G V
Ophthalmology Department, Bradford Royal Infirmary, Bradford, West Yorkshire BD9 6RJ, UK.
School of Electrical and Electronic Engineering, University of Newcastle upon Tyne and Institute for Molecular Medicine, Huntington Beach, CA, UK.
Cancer Lett. 2015 Mar 28;358(2):93-99. doi: 10.1016/j.canlet.2014.12.026. Epub 2014 Dec 18.
HER2 positive breast cancers have been shown to have a greater propensity to metastasise to the brain. This may be due to several reasons, including the creation of a "sanctuary-site" for tumour in the brain following trastuzumab therapy. Elucidating the mechanism of this phenomenon may aid the prevention or intervention and treatment of such metastases, but research is limited by the deficiency and diminished access of CNS tissue. However, CNS penetrable HER2 receptor antagonists such as lapatinib and intrathecal administration of trastuzumab might benefit patients, and are worthy of further investigation. New avenues of molecular approach have focused on manipulating signal transduction system involved in HER2 function. The importance of systemic therapies and those targeted to metastatic lesions is emphasised and evaluated here.
已证明HER2阳性乳腺癌更易于转移至脑部。这可能有多种原因，包括在曲妥珠单抗治疗后在脑部形成肿瘤的“庇护所”。阐明这一现象的机制可能有助于预防或干预及治疗此类转移，但研究受到中枢神经系统组织的缺乏和获取受限的限制。然而，可穿透中枢神经系统的HER2受体拮抗剂，如拉帕替尼和鞘内注射曲妥珠单抗，可能使患者受益，值得进一步研究。分子方法的新途径已聚焦于操纵参与HER2功能的信号转导系统。本文强调并评估了全身治疗以及针对转移性病变的治疗的重要性。
